BFM
MDGL icon

Boothbay Fund Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Boothbay Fund Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-132
Closed -$1.57M – 1348
2020
Q3 		$1.57M Buy
132
+76
+136% +$8.25K 0.09% 288
2020
Q2 		$634K Buy
+56
New +$5.51K 0.04% 518
2019
Q3 		– Sell
-287
Closed -$3.01M – 851
2019
Q2 		$3.01M Sell
287
-177
-38% -$19K 0.27% 87
2019
Q1 		$5.81M Sell
464
-212
-31% -$26.4K 0.56% 28
2018
Q4 		$7.62M Buy
676
+474
+235% +$73.4K 1.11% 15
2018
Q3 		$4.33M Buy
202
+75
+59% +$18.8K 0.43% 51
2018
Q2 		$3.55M Buy
+127
New +$22.3K 0.31% 63

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boothbay Fund Management's MDGL Position: Q4 2025 in Review

Boothbay Fund Management sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2025, closing a stake of 1,117 shares — an estimated $512K sold.

Boothbay Fund Management first reported a position in MDGL in Q1 2019 and held it in 12 quarters. The position peaked at $2.18M in Q2 2020. 387 funds tracked by Wall St. Rank hold MDGL as of Q4 2025.

  • Boothbay Fund Management reported no remaining Madrigal Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 1,117 Madrigal Pharmaceuticals shares in Q4 2025, an estimated $512K.
  • Boothbay Fund Management first reported a position in Madrigal Pharmaceuticals in Q1 2019 and held it in 12 quarters.
  • Boothbay Fund Management's Madrigal Pharmaceuticals position peaked at $2.18M in Q2 2020.
  • 387 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2025.

Based on Boothbay Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.